Himalaya Nutravedics India IPO Day 2: GMP ₹0
Welcome back to our daily deep dive into the Himalaya Nutravedics India SME IPO! As we wrap up Day 2 of the subscription period, the picture remains remarkably consistent. With the IPO open for just one more day, investors are still weighing their options. Let’s break down what the numbers are telling us.
| Date | GMP | Est. Listing |
|---|---|---|
| 28 Sep | ₹0 | ₹106 |
Subscription Status
As of the close of Day 2, Himalaya Nutravedics India’s IPO is showing 0x subscription across all categories: Retail, NII (Non-Institutional Investors), and QIB (Qualified Institutional Buyers). This means that not a single share has been subscribed for yet by any segment of investors. For a retail investor looking to get in, this might seem unusual, especially with the IPO closing tomorrow. Typically, by Day 2, we’d expect to see at least some traction, particularly in the retail or NII segments. The complete lack of subscriptions across the board, including from QIBs who are often early movers, is something to observe closely. It could indicate a cautious market sentiment, or perhaps investors are waiting for a last-minute surge, which is a less common but not impossible scenario for SME IPOs. The lot size is 1200 shares, and the issue price is fixed at ₹106 per share.
| Category | Subscription | Progress |
|---|---|---|
| Retail | 0.00x | |
| NII / HNI | 0.00x | |
| QIB | 1.00x | |
| Total | 1.00x |
GMP Update
Interestingly, the Grey Market Premium (GMP) for Himalaya Nutravedics India IPO remains unchanged at ₹0. Yesterday, the GMP was also ₹0, and it’s stayed that way. A GMP of ₹0 suggests that the market isn’t currently factoring in any listing gains. This aligns with the subdued subscription numbers we’re seeing. When GMP is ₹0, it often means the market perceives the issue price as fair, or there’s uncertainty about demand post-listing. The expected listing price is currently pegged at the issue price of ₹106, reflecting this flat GMP. We’ll be keeping a close eye on any shifts in the GMP as the final day of subscription unfolds, though at this point, significant movement seems unlikely without a change in subscription momentum.
Should You Apply?
This is where things get interesting. We’re at the cusp of the IPO closing, and the subscription numbers are flat, with a GMP of ₹0. For many investors, especially those looking for quick listing gains, this scenario might be a cause for pause. The lack of subscription interest, coupled with no premium in the grey market, doesn’t paint a picture of overwhelming demand. However, this isn’t to say there’s no potential. SME IPOs can sometimes see a last-minute rush, particularly from retail investors who might be swayed by the company’s fundamentals or a final push from the management. The issue price of ₹106 is the benchmark, and with no GMP, the listing is anticipated to be around this figure. As always, it’s crucial to do your own due diligence on Himalaya Nutravedics India’s business model, financials, and future prospects. Remember, SEBI registered advisors always recommend investing based on thorough research and your risk appetite, not solely on GMP or subscription levels. The IPO closes on 2026-09-24, so you still have time to make an informed decision.